Transcatheter aortic valve replacement (TAVR) with the CoreValve® system (Medtronic) and surgical aortic valve replacement (SAVR) show similar 5-year survival and stroke rates in high-risk patients, as shown by the MCV-US-2009-01 study (NCT01240902). Most patients remained free from severe structural valve deterioration (SVD) and valve reinterventions (VR).
Anticoagulation, which is often provided for atrial fibrillation (AF), decreases the risk of bioprosthetic valve dysfunction (BVD) after transcatheter aortic valve replacement (TAVR), according to the results of the FRANCE-TAVI registry study. Male gender, chronic kidney disease (CKD), and atrial fibrillation (AF) have the highest impact on the 3-year mortality due to BVD after TAVR.
Real-life use of edoxaban (Lixiana®, Daiichi Sankyo) in Asian atrial fibrillation (AF) patients significantly lowered the risk of ischaemic stroke (IS), intracranial haemorrhage (ICH), hospitalisation for gastrointestinal (GI) bleeding, hospitalisation for major bleeding, and all-cause death when compared to warfarin. This was concluded by the Korean investigators in the Journal of the American College of Cardiology. The benefits were consistent in the various high-risk subgroups.
Exclusive subscriber download.